Zimbabwe has declined a significant US healthcare agreement valued at $367m (272 million pounds) over five years over the United States' demand for sensitive biological samples.
The decision came to light after a internal memorandum dated December was leaked, revealing that President Emmerson Mnangagwa deemed the deal was "lopsided".
A government spokesperson has since stated that the United States was requesting genetic material for scientific study and profit while was not willing to guarantee the benefits from future medical innovations.
"We must now begin the difficult and regrettable task of winding down our health assistance in Zimbabwe," remarked American envoy to Zimbabwe Pamela Tremont in a statement.
The US Embassy said the United States had donated more than $1.9bn in health funding to Zimbabwe during the past two decades.
A medical body in Zimbabwe has urged more negotiations to find a agreement acceptable to all parties so the country's vital HIV programme can be sustained.
Wider Background
This development comes after a comparable situation in Kenya, where a court halted a similar deal with the US after concerns were filed about the security of Kenyans' medical information.
Since resuming office last year, US President Donald Trump has drastically cut overseas assistance and shut down the key foreign aid agency.
The agency had overseen assistance for the American government, but Trump claimed its expenditure was "wasteful" and his administration was pursuing government-to-government deals to enhance transparency and responsibility.
As per reports, 16 African countries have to date signed similar agreements, constituting more than $18.3bn in new funding.
Specifics of the Declined Agreement
This assistance for Zimbabwe was intended to funded "combating HIV/Aids, tuberculosis, malaria, healthcare for mothers and children, and preparing for epidemics".
"We believe this collaboration might have yielded immense benefits for the people of Zimbabwe, particularly the 1.2 million currently receiving antiretroviral therapy through US-supported programmes," the Ambassador commented.
However, government spokesperson Nick Mangwana maintained the arrangement was "unequal".
"Zimbabwe was being asked to share its biological resources and data over an extended period, without any equivalent assurance of benefiting from any scientific breakthroughs – such as new medicines or tests – that could result from that shared data," Mangwana explained.
"Put simply, our nation would provide the basic resources for medical research with no assurance that the final treatments would be available to our population if a new disease outbreak arise."
Sovereignty and Global Health
Mangwana further pointed out that the American exit from the global health body and its push of one-on-one health agreements were upending structures previously set up through the global organization.
The spokesperson gave as an example its Pathogen Access and Benefit Sharing system created to deal with potential pandemics.
"This framework is designed to ensure that when a nation contributes its information, the benefits – including medicines and cures – are shared equitably, not commercialised exclusively by those with the capability to create them."
These objections regarding the US deal "must not be interpreted as opposition to America," Mangwana stressed.
"We are open to continued dialogue with our US partners on how future collaboration could be structured in a way that honours the sovereignty and dignity of both nations."
Health Experts Reaction
A leading public health body stated it understood the government's concerns, but recommended that negotiations must proceed given that much of the nation's HIV programmes relied on international support.
"If specific concerns exist, including those relating to information security or implementation frameworks, these can often be resolved through detailed discussion and negotiated safeguards," the group commented.
The situation underscores the complex challenges between accepting vital international aid and protecting a country's data in an increasingly data-driven world.